Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience.

Research and practice in thrombosis and haemostasis·2026

Same author

Refining current risk stratification guidelines for pregnant women with Fontan circulation: lessons from PROFAT registry.

European journal of preventive cardiology·2025

Same author

Recurrent thrombosis and major bleeding in children treated for VTE.

Blood advances·2025

Same author

Prothrombin prevents fatal T cell-dependent anemia during chronic virus infection of mice.

JCI insight·2025

Same author

Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery.

Journal of thrombosis and haemostasis : JTH·2024

Same author

Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity.

Journal of thrombosis and haemostasis : JTH·2024

Search research articles

Related Experiment Video

Updated: Sep 21, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Hemostasis and tumor immunity.

Rachel Cantrell¹, Joseph S Palumbo¹

¹Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine Cincinnati Ohio USA.

Research and Practice in Thrombosis and Haemostasis

|June 1, 2022

Summary

This summary is machine-generated.

Cancer and the hemostatic system have a reciprocal relationship, impacting cancer progression and treatment. Understanding crosstalk between hemostasis and adaptive immunity is key for safer cancer therapies and improved outcomes.

Keywords:

cancer hemostasis immune system thromboembolism tumor

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Related Experiment Videos

Last Updated: Sep 21, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Area of Science:

Oncology
Hematology
Immunology

Background:

Cancer and the hemostatic system exhibit a reciprocal relationship, with cancer promoting hemostatic dysregulation and hemostatic components influencing cancer pathogenesis.
Mechanisms underlying this relationship involve crosstalk between hemostatic and immune systems, particularly innate immunity.
Emerging evidence highlights the role of hemostasis in adaptive immunity within cancer biology.

Purpose of the Study:

To review the evidence for crosstalk between hemostatic and adaptive immune system components in cancer.
To discuss the implications of this relationship for adaptive immunity-based cancer therapies.
To explore strategies for improving cancer treatment safety and efficacy by targeting these interactions.

Main Methods:

Literature review of preclinical and clinical studies.
Analysis of data on thromboembolic complications associated with cancer therapies.
Examination of mechanisms by which hemostatic components regulate adaptive immune functions.

Main Results:

Adaptive immunity-based cancer therapies, like immune checkpoint inhibitors, are linked to increased thromboembolic risk.
Hemostatic system components modulate adaptive immune responses, affecting tumor progression.
Crosstalk between hemostasis and adaptive immunity plays a significant role in cancer biology and treatment.

Conclusions:

Understanding the interplay between hemostasis and adaptive immunity is crucial for cancer therapy.
Targeting these interactions may reduce thromboembolic complications, enhancing the safety of current therapies.
Further research can identify novel therapeutic targets to improve adaptive immune-based cancer treatments.